Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today presented new positive clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Willi syndrome (PWS) at ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.
An oral presentation titled, “Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome,” presented by Dr. Eric Felner, Emory University School of Medicine, summarized data demonstrating positive hormonal, cardiometabolic and body composition changes in PWS patients following one year of treatment with DCCR. The patients were treated in C601, a Phase 3 randomized, double-blind, placebo-controlled study and C602, its ongoing open-label extension.
Patients (n=82) experienced improvements in body composition, as evidenced by statistically significant changes in lean body mass (p<0.0001) and the ratio of lean body mass to fat mass (p=0.0005), based on DXA scanning. These changes were accompanied by reduced levels of leptin (p<0.0001), fasting insulin (p=0.0004) and an improvement in insulin sensitivity (HOMA IR p=0.0033), likely related to a combination of reduced fat mass and improved leptin resistance. A statistically significant increase of adiponectin (p<0.0001), a cardioprotective marker, was also observed. Similar effects were observed in obese participants (n=40) enrolled in these studies.
https://finance.yahoo.com/news/soleno-therapeutics-presents-long-term-200500320.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.